Yellow fever vaccine: worthy friend or stealthy foe?

Expert Review of Vaccines

Volumn 15, Issue 6, 2016, Pages 681-691

  Seligman, Stephen J ^a,b   Casanova, Jean Laurent ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

vaccine; YEL AVD; Yellow fever; yellow fever vaccine associated viscerotropic disease

Indexed keywords

RAIN; YELLOW FEVER VACCINE; LIVE VACCINE;

AFRICA; AFRICA SOUTH OF THE SAHARA; ARTICLE; CLINICAL DECISION MAKING; DRUG SAFETY; ENDEMIC DISEASE; GENOME ANALYSIS; HIGH RISK POPULATION; HUMAN; INCIDENCE; MEDICAL DOCUMENTATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOUTH AMERICA; TRAVEL; VACCINATION; VACCINATION REACTION; YELLOW FEVER; YELLOW FEVER VACCINE ASSOCIATED VISCEROTROPIC DISEASE; IMMUNOLOGY;

AFRICA; HUMANS; SOUTH AMERICA; VACCINES, ATTENUATED; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84975125339     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1180250     Document Type: Article

References (52)

1. T.P.Monath Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11(4):427–448.•• A comprehensive analysis of the field setting the stage for future developments.
2. T.P.Monath, M.Gershman, J.E.Staples, et al. Yellow fever vaccine. In: S.A.Plotkin, W.Orenstein, P.A.Offit, editors. Vaccines. Philadelphia: Elsevier-Saunders; 2013. p. 870–968.•• An encyclopedic presentation of data relevant to yellow fever vaccine.
3. S.J.Seligman. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769–5775.• A helpful evaluation of risk groups for YEL-AVD that has usefulness for vaccine administration.
4. T.P.Monath, P.F.Vasconcelos. Yellow fever. J Clin Virol. 2015;64:160–173.
5. R.De Menezes Martins, M.Da Luz Fernandes Leal, A.Homma. Safety of yellow fever vaccine. Hum Vaccin Immunother. 2015;11(9);2183–2187.
6. A.S.Beck, A.D.Barrett. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015;14(11):1479–1492.
7. J.E.Bryant, E.C.Holmes, A.D.Barrett. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007;3(5):e75.
8. B.R.Miller, C.J.Mitchell, M.E.Ballinger. Replication, tissue tropisms and transmission of yellow fever virus in Aedes albopictus. Trans R Soc Trop Med Hyg. 1989;83(2):252–255.
9. F.Engelmann, L.Josset, T.Girke, et al. Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl Trop Dis. 2014;8(11):e3295.
10. Feral rhesus macaque. Available from: https://en.wikipedia.org/wiki/Feral_rhesus_macaque.
11. Case of yellow fever in monkeys is confirmed in Tocantins. Available from: http://www.promedmail.org/direct.php?id=3551886.
12. The early history of yellow fever. Available from: http://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1004&context=yellow_fever_symposium.
13. M.C.Crosby. The American plague. Berkley (NY): Berkley Books; 2007.•• A fascinating history both of the devastation caused by yellow fever epidemics, particularly the Memphis, Tennessee epidemic of 1878 and of the experiments of Walter Reed establishing that Aedes aegypti was the vector of urban yellow fever.
14. Yellow fever the plague of Memphis. Available from: http://historic-memphis.com/memphis-historic/yellow-fever/yellow-fever.html.
15. Yellow fever and the Reed commission. Available from: http://exhibits.hsl.virginia.edu/yellowfever/mosquitoes/.
16. T.P.Monath, R.B.Craven, A.Adjukiewicz, et al. Yellow fever in the Gambia, 1978–1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980;29(5):912–928.
17. P.F.Vasconcelos, E.J.Luna, R.Galler, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358(9276):91–97.
18. M.Martin, T.F.Tsai, B.Cropp, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358(9276):98–104.
19. R.C.Chan, D.J.Penney, D.Little, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358(9276):121–122.
20. S.J.Seligman, J.E.Cohen, Y.Itan, et al. Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data. Am J Trop Med Hyg. 2014;90(2):267–271.
21. T.P.Monath. Dengue and yellow fever–challenges for the development and use of vaccines. N Engl J Med. 2007;357(22):2222–2225.
22. J.L.Casanova. Severe infectious diseases of childhood as monogenic inborn errors of immunity. Proc Natl Acad Sci U S A. 2015;112(51):E7128–7137.
23. J.L.Casanova. Human genetic basis of interindividual variability in the course of infection. Proc Natl Acad Sci U S A. 2015;112(51):E7118–7127.
24. E.S.Moreno, R.Spinola, C.H.Tengan, et al. Yellow fever epizootics in non-human primates, Sao Paulo state, Brazil, 2008–2009. Rev Inst Med Trop Sao Paulo. 2013;55(1):45–50.
25. L.Markoff. Yellow fever outbreak in Sudan. N Engl J Med. 2013;368(8):689–691.
26. CDC - Yellow Fever. Available from: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever.
27. S.J.Seligman. Yellow fever - africa (25): Angola comment [Internet]. 2016. [cited 2016 Mar 19]. Available from: http://www.promedmail.org/
28. P.Cottin, M.Niedrig, C.Domingo. Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev Vaccines. 2013;12(11):1351–1368.
29. R.de Menezes Martins, D.L.D.S.Maia, E.M.dos Santos, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia Vaccinol. 2010;2:178–183.• Although published in an obscure journal, the article contains some of the most significant data on YEL-AVD.
30. A.Y.Khromava, R.B.Eidex, L.H.Weld, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256–3263.
31. N.P.Lindsey, B.A.Schroeder, E.R.Miller, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077–6082.
32. Collaborative group for studies of yellow fever V. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015;110(6):771–780.
33. A.C.Campi-Azevedo, C.Costa-Pereira, L.R.Antonelli, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12(2):491–502.
34. J.E.Staples, J.A.BocchiniJr, L.Rubin, et al. Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647–650.
35. S.Berrih-Aknin, R.Le Panse. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90–100.
36. Mayo Clinic - Myasthenia gravis. Available from: http://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/basics/causes/con-20027124.
37. Genetics home reference - Myasthenia gravis. Available from: https://ghr.nlm.nih.gov/condition/myasthenia-gravis.
38. D.Grob, N.Brunner, T.Namba, et al. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–149.
39. Dry season. Available from: https://en.wikipedia.org/wiki/Dry_season.
40. Weather. Available from: https://weather.com/weather.• May be used to elucidate weather conditions in endemic areas including parts of countries.
41. C.Biscayart, M.E.Carrega, S.Sagradini, et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine. 2014;32(11):1266–1272.
42. Yellow fever reported cases. Available from: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidenceyfever.html.
43. Anon. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA. 1966;198(6):671–672.
44. J.L.Belsher, P.Gay, M.Brinton, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine. 2007;25(50):8480–8485.
45. J.L.Casanova, M.E.Conley, S.J.Seligman, et al. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137–2149.
46. J.G.Breugelmans, R.F.Lewis, E.Agbenu, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31(14):1819–1829.
47. G.Dunn, D.Klapsa, T.Wilton, et al. Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. PLoS Pathog. 2015;11(8):e1005114.
48. K.Kengsakul, K.Sathirapongsasuti, S.Punyagupta. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85(1):131–134.
49. T.P.Monath, E.Fowler, C.T.Johnson, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364(14):1326–1333.
50. R.C.Pereira, A.N.Silva, M.C.Souza, et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine. 2015;33(35):4261–4268.
51. M.MacielJr, S.Cruz Fda, M.T.Cordeiro, et al. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis. 2015;9(4):e0003693.
52. A.C.Campi-Azevedo, P.de Almeida Estevam, J.G.Coelho-Dos-Reis, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014;14:391.